The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) last traded at $0.84, up 3.52% from the previous session.
Data from the available sources indicates that Aclaris Therapeutics Inc (NASDAQ:ACRS) is covered by 9 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $27.00 and a low of $1.00, we find $5.50. Given the previous closing price of $0.81, this indicates a potential upside of 579.01 percent. ACRS stock price is now -83.25% away from the 50-day moving average and -89.76% away from the 200-day moving average. The market capitalization of the company currently stands at $59.72M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
In total, 5 analysts have assigned it a hold rating, and 4 have given it a buy rating. Brokers who have rated the stock have averaged $9.00 as their price target over the next twelve months.
In other news, Monahan Joseph, Chief Scientific Officer sold 6,000 shares of the company’s stock on Oct 23. The stock was sold for $30,460 at an average price of $5.08. Upon completion of the transaction, the Chief Scientific Officer now directly owns 129,724 shares in the company, valued at $0.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 06, Chief Financial Officer Balthaser Kevin bought 9,490 shares of the business’s stock. A total of $74,971 was incurred on buying the stock at an average price of $7.90. This leaves the insider owning 15,461 shares of the company worth $12987.24. Insiders disposed of 204,367 shares of company stock worth roughly $0.17 million over the past 1 year. A total of 17.30% of the company’s stock is owned by insiders.
With an opening price of $0.8242 on Friday morning, Aclaris Therapeutics Inc (NASDAQ: ACRS) set off the trading day. During the past 12 months, Aclaris Therapeutics Inc has had a low of $0.59 and a high of $18.54. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 4.50, and a quick ratio of 4.50. The fifty day moving average price for ACRS is $4.8905 and a two-hundred day moving average price translates $8.1699 for the stock.
The latest earnings results from Aclaris Therapeutics Inc (NASDAQ: ACRS) was released for Sep, 2023. According to the Diagnostics & Research Company, earnings per share came in at -$0.41, beating analysts’ expectations of -$0.48 by 0.07. This compares to -$0.30 EPS in the same period last year. The net profit margin was -534.83% and return on equity was -60.94% for ACRS. The company reported revenue of $9.28 million for the quarter, compared to $19.02 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -51.19 percent. For the current quarter, analysts expect ACRS to generate $4.02M in revenue.
Aclaris Therapeutics Inc(ACRS) Company Profile
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
